DE LERMA BARBARO, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 4.775
EU - Europa 4.721
AS - Asia 962
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 1
Totale 10.466
Nazione #
US - Stati Uniti d'America 4.671
IT - Italia 2.484
UA - Ucraina 953
TR - Turchia 373
SE - Svezia 366
VN - Vietnam 328
FI - Finlandia 246
CN - Cina 222
DE - Germania 219
IE - Irlanda 204
CA - Canada 103
FR - Francia 100
GB - Regno Unito 98
IN - India 22
JP - Giappone 12
RU - Federazione Russa 11
BE - Belgio 10
NL - Olanda 9
CH - Svizzera 6
EU - Europa 5
AT - Austria 4
RS - Serbia 4
CZ - Repubblica Ceca 2
ES - Italia 2
NZ - Nuova Zelanda 2
AZ - Azerbaigian 1
CO - Colombia 1
DK - Danimarca 1
GL - Groenlandia 1
GR - Grecia 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
SG - Singapore 1
TW - Taiwan 1
Totale 10.466
Città #
Milan 1.826
Jacksonville 723
Chandler 529
Fairfield 453
Woodbridge 354
Ashburn 314
Wilmington 257
Princeton 245
Ann Arbor 229
Izmir 229
Nyköping 216
Dublin 204
Dearborn 194
Seattle 188
Houston 167
Dong Ket 155
Cambridge 134
Rome 125
Como 102
Toronto 93
Beijing 92
San Mateo 92
New York 58
San Diego 55
Ogden 38
Düsseldorf 29
Verona 23
Pune 22
Boardman 20
Hefei 20
Los Angeles 18
Nanjing 15
London 13
Helsinki 12
Brussels 10
Guangzhou 10
Kunming 10
Tokyo 10
Norwalk 9
Jinan 8
Redwood City 8
Ponte Lambro 7
Washington 7
Auburn Hills 6
Rozzano 6
Villanova D'asti 6
Falls Church 5
Fuzhou 5
Vanzaghello 5
Zhengzhou 5
Belgrade 4
Casorezzo 4
Changsha 4
Hebei 4
Hounslow 4
Seveso 4
Voghera 4
Xian 4
Amsterdam 3
Chiswick 3
Costa Mesa 3
Edinburgh 3
Huzhou 3
Indiana 3
Nanchang 3
Ottawa 3
Phoenix 3
San Francisco 3
Shenyang 3
Varese 3
Wenzhou 3
Zurich 3
Chengdu 2
Chongqing 2
Frankfurt am Main 2
Graz 2
Magnago 2
Montreal 2
Monza 2
Muggiò 2
Prescot 2
Quzhou 2
Redmond 2
Rudolfstetten 2
Sesto San Giovanni 2
Simi Valley 2
Vienna 2
Wandsworth 2
West Jordan 2
Wuhan 2
Ürümqi 2
Acton 1
Atlanta 1
Auckland 1
Baku 1
Baotou 1
Bari 1
Berlin 1
Biella 1
Birmingham 1
Totale 7.482
Nome #
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae) 165
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human 157
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy 155
The MHC class II transactivator: prey and hunter in infectious diseases 154
New strategies of mammary cancer vaccination 147
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells 143
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory. 141
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory 132
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication 130
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review) 129
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis 127
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. 127
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle 126
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. 125
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae 121
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR 120
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2 120
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory 118
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions 111
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy 109
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines 109
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan 108
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis 107
MHC immunoevasins: protecting the pathogen reservoir in infection 106
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y 106
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules 102
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis 102
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay 102
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells. 101
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions 100
The complex liaison between cachexia and tumor burden 99
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory. 98
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells 98
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA 94
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan 91
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication 91
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules 90
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA 90
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA 88
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages 88
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer 88
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells 88
Regulation of HLA antigen expression in HIV infected cells 88
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy. 87
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene 86
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia. 86
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions 85
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis 84
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy. 84
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis 83
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. 83
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1 83
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy. 83
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT 83
Analysis of microchimerism in thyroid autoimmune diseases 83
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis 83
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan 82
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication 82
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica 81
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation 81
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat 81
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication 81
The complex liaison between vulnerability to cachexia and tumor burden. 81
Regulation of HLA antigen expression in phagocytes with mycobacteria 80
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA) 80
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections 80
Imaging guided percutaneous microwave ablation of tumors. 77
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication 77
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR 76
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells 76
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection. 76
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis. 76
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB 75
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA 74
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication 74
Regulation of HLA antigen expression in phagocytes treated with mycobacteria 74
HLA-DQ expression is differently regulated from -DR and -DP 73
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA 73
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA 73
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA) 73
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge. 72
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells 71
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated 70
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator 70
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection 69
Temporal and quantitative relations between CIITA and HLA class II expression 69
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA 69
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan. 68
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells. 67
The immunological basis of tumor rejection and anti-tumor memory to neoplasias of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. 67
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II 67
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y 66
La fagocitosi di Mycobacterium Tuberculosis ha effetti opposti sull'espressione di superficie delle molecole HLA di classe I e di classe II 66
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ 66
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat 65
Reverse correlation between HTLV-II replication and expression of CIITA, the major regulator of HLA class II transcription 65
Non-replicating MHC Class II- CIITA-positive mammary adenocarcinoma cells act as an effective anti-tumor-preventive vaccine by inducing long-lasting tumor-specific CD8+ T cells and potent CD4+ T helper cells. 64
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan 64
Induction of tumor rejection by gene transfer of the MHC class II transactivator CIITA 64
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1 64
Totale 9.183
Categoria #
all - tutte 34.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.084


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019313 0 0 0 0 0 0 0 0 0 0 0 313
2019/20201.606 51 39 56 273 69 176 257 240 97 184 17 147
2020/20211.447 14 152 8 150 24 161 44 143 264 59 138 290
2021/20221.101 141 133 106 111 22 19 41 95 53 128 91 161
2022/20231.408 151 66 123 167 97 319 0 188 173 37 51 36
2023/20242.822 452 438 505 488 499 220 24 26 107 22 2 39
Totale 10.515